PRECOG confirmed the association between SHN3 expression and shorter life expectancy in GBM patients, as well as a good correlation between high SHN3 and IL13Rα2 expression and poor prognosis in multiple cancers, particularly in tumors of the central nervous system (GBM, astrocytoma), hematological malignancies, melanoma, and some lung cancers, (Fig. 7D). Here, IL13RA2 is linked to hematologic disorder.